ALK and non-small cell lung carcinoma: An Italian multicentric analysis that investigated the activity of radiotherapy in patients with ALK-/EGFR-mutated metastatic NSCLC confirmed that stereotactic RT (HR 0.355, CI 95% 0.212–0.595; p < 0.001) and median duration of TKI superior to 14 months (HR 0.17, 95% CI 0.10–0.30; p < 0.001) were independent factors related to better OS [29].